1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Drs. Denton, Leask, and Abraham contributed equally to this work.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Contribution of activin receptor–like kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts
Article first published online: 30 MAR 2006
DOI: 10.1002/art.21725
Copyright © 2006 by the American College of Rheumatology
Additional Information
How to Cite
Chen, Y., Shi-Wen, X., Eastwood, M., Black, C. M., Denton, C. P., Leask, A. and Abraham, D. J. (2006), Contribution of activin receptor–like kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis & Rheumatism, 54: 1309–1316. doi: 10.1002/art.21725
Publication History
- Issue published online: 30 MAR 2006
- Article first published online: 30 MAR 2006
- Manuscript Accepted: 19 DEC 2005
- Manuscript Received: 2 SEP 2005
Funded by
- Scleroderma Foundation
- Scleroderma Society
- Arthritis Research Campaign
- Raynaud's and Scleroderma Association Trust
- British Heart Foundation
- Welton Foundation
- Canadian Institutes of Health Research. Grant Number: MOP-77603
- University of Western Ontario
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , Increased Accumulation of Extracellular Thrombospondin-2 Due to Low Degradation Activity Stimulates Type I Collagen Expression in Scleroderma Fibroblasts, The American Journal of Pathology, 2012, 180, 2, 703
- 2, , , Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants, Cardiology Research and Practice, 2012, 2012, 1
- 3, , , , , , , , , , Activation of the Activin A-ALK-Smad pathway in systemic sclerosis, Journal of Autoimmunity, 2011, 36, 3-4, 181
- 4, , , , , , , Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts, Journal of Cellular Physiology, 2011, 226, 12Direct Link:
- 5, , , , Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy, Autoimmunity Reviews, 2011, 10, 5, 267
- 6, , , , , , , , , Loss of PTEN Expression by Dermal Fibroblasts Causes Skin Fibrosis, Journal of Investigative Dermatology, 2011, 131, 10, 1996
- 7, , , , , Phospho-Smad1 modulation by nedd4 e3 ligase in BMP/TGF-β signaling, Journal of Bone and Mineral Research, 2011, 26, 7Direct Link:
- 8, , , , , , , , , , , , , , , , , Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF), Clinica Chimica Acta, 2011, 412, 23-24, 2211
- 9, Possible strategies for anti-fibrotic drug intervention in scleroderma, Journal of Cell Communication and Signaling, 2011, 5, 2, 125
- 10, , , , , , , Pulmonary microvascular endothelial cells from bleomycin-induced rats promote the transformation and collagen synthesis of fibroblasts, Journal of Cellular Physiology, 2011, 226, 8Direct Link:
- 11, , , , , , , , , Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism, Fibrogenesis & Tissue Repair, 2011, 4, 1, 9
- 12
- 13, , , , , , , , Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate, Rheumatology, 2010, 49, 11, 2024
- 14, , , , , , The human α11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-β1 in a Smad- and Sp1-dependent manner, Matrix Biology, 2010, 29, 3, 166
- 15, , , , , Use of a TGFÂ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFÂ signaling in tumor promotion and progression, Carcinogenesis, 2010, 31, 12, 2127
- 16, , , , Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?, Journal of Cell Communication and Signaling, 2009, 3, 2, 89
- 17, , , , Overview of pathogenesis of systemic sclerosis, Rheumatology, 2009, 48, Supplement 3, iii3
- 18, , , , , , , , , , , , , Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen, Arthritis & Rheumatism, 2009, 60, 7Direct Link:
- 19, , , , , , Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts, Rheumatology, 2009, 49, 2, 259
- 20, Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma, Journal of Cell Communication and Signaling, 2009, 4, 2, 111
- 21, , , , , , Akt Blockade Downregulates Collagen and Upregulates MMP1 in Human Dermal Fibroblasts, Journal of Investigative Dermatology, 2008, 128, 8, 1906
- 22, , , , , , , Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis, Arthritis & Rheumatism, 2008, 58, 9Direct Link:
- 23, , Fibrosis in Systemic Sclerosis, Rheumatic Disease Clinics of North America, 2008, 34, 1, 115
- 24, , , , , , , , , , , , , , , Heparan sulfate–dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts, Arthritis & Rheumatism, 2008, 58, 2Direct Link:
- 25, , , Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis, Cytokine & Growth Factor Reviews, 2008, 19, 2, 133
- 26, , , , Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells, Journal of Cell Communication and Signaling, 2008, 2, 1-2, 49
- 27, , , , , , , , Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate, Arthritis & Rheumatism, 2008, 58, 8Direct Link:
- 28, Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma, Cellular Signalling, 2008, 20, 8, 1409
- 29, , Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK, Journal of Cell Communication and Signaling, 2007, 1, 2, 85
- 30, , , , , , , , , , , , , Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts, Matrix Biology, 2007, 26, 8, 625
- 31, , , , , , , , , Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts, Arthritis & Rheumatism, 2007, 56, 12Direct Link:
- 32, , , , , , Increased Expression of Wnt2 and SFRP4 in Tsk Mouse Skin: Role of Wnt Signaling in Altered Dermal Fibrillin Deposition and Systemic Sclerosis, Journal of Investigative Dermatology, 2007, 128, 4, 871
- 33, , Molecular pathways as novel therapeutic targets in systemic sclerosis, Current Opinion in Rheumatology, 2007, 19, 6, 568
- 34, , Systemic sclerosis: a prototypic multisystem fibrotic disorder, Journal of Clinical Investigation, 2007, 117, 3, 557
- 35, , Therapeutic transforming growth factor-β blockade in systemic sclerosis, Future Rheumatology, 2006, 1, 5, 617